Innovata Biomed Ltd has developed an alternative device, the Clickhaler®, which is a multiple-dose dry powder inhaler (DPI). The present study compared patient acceptability of the salbutamol ...

Teva has launched a digitally-enabled inhaler in the UK, the first European market for the device, for use by patients with asthma and chronic obstructive pulmonary disorder (COPD). The GoResp ...

Teva has launched new digital inhaler and drug combination in the US, containing built-in sensors that connect to a phone to help manage asthma and COPD symptoms. Israel-based Teva said the ...

In October 2023, Teva Pharmaceuticals filed a patent infringement lawsuit against Amneal Pharmaceuticals alleging that their generic version of Teva’s ProAir® HFA inhaler infringed upon the ...

With the denial of this petition, Teva is required to follow the district court’s delisting order and remove its inhaler patents — including U.S. Patent Nos. 8,132,712; 9,463,289; 9,808,587 ...

but what I want to remind you that's because Teva is a biopharma company. it's not a generics company and that's why -- so ICS/SABA, the DARI study is a dual action rescue inhaler. And as you ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 monoclonal antibody targeting TL1A, for the ...

Of the 233 patients enrolled, 208 used pMDI and 25 used turbuhaler® inhaler devices for their bronchodilator therapy. Over 80% of patients had been using their standard inhaler for more than 1 year.

Many inhalers that are vital for patients with asthma or COPD are associated with societal harms that can worsen the very diseases the products are designed to treat. How can this dilemma be resolved?

However for years now, my inhalers will just stop working without warning. Sometimes with 30 puffs left. Sometimes almost full. This is a very dangerous situation, and yet after contacting Teva ...

Teva Pharmaceutical Industries (NYSE:TEVA) saw its stock price move up 14% over the last week, a notable jump attributed partially to recent regulatory milestones. The U.S. FDA's acceptance of a ...